Loading organizations...
Béa Fertility has raised $5.0M across 2 funding rounds.
Key people at Béa Fertility.
Béa Fertility has raised $5.0M in total across 2 funding rounds.
Béa Fertility is a London-based femtech company that develops clinical-grade, at-home intracervical insemination devices and structured fertility treatment kits guided by clinical coaches. The direct-to-consumer business provides an accessible and affordable alternative to traditional in-vitro fertilization clinics, having successfully delivered 2,700 treatment cycles and supported 1,250 patients across its reproductive health platform to date. Following two years of extensive research and development involving 90 hardware prototypes, the medical device company secured FDA Class 2 clearance and achieved a 39.28% pregnancy rate in its single-arm clinical study. To support its growth, the enterprise has raised £3 million in total venture capital funding, reaching a £19 million valuation with financial backing from institutional investors including Octopus Ventures, JamJar Investments, and Forward Partners. Béa Fertility was officially founded in London in 2020 by Tess Cosad, George Thomas, and David O'Rourke.
Béa Fertility has raised $5.0M across 2 funding rounds. Most recently, it raised $4.0M Bea Fertility - Series U in July 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2023 | $4M Series U | — | Calm/Storm Ventures, Frontline Ventures, QVentures | Announced |
| Mar 1, 2021 | $1M Seed | — | Calm/Storm Ventures, Frontline Ventures, QVentures | Announced |
Key people at Béa Fertility.
Béa Fertility has raised $5.0M in total across 2 funding rounds.
Béa Fertility's investors include Calm/Storm Ventures, Frontline Ventures, QVentures.
Béa Fertility is a femtech startup revolutionizing early-stage fertility care by delivering clinic-grade, at-home treatments that bridge the gap between natural conception attempts and invasive IVF.[1][2] The company offers FDA-cleared intracervical insemination (ICI) kits, including devices for semen placement near the cervix, structured treatment cycles, and unlimited access to clinical coaches, serving individuals and couples facing unexplained infertility or barriers to traditional care.[1][2][7] It solves the "wait 12 months" frustration of conventional systems by providing affordable, evidence-based interventions from day one, with a reported 39.28% pregnancy rate in studies and strong growth: 2,700 cycles delivered and 1,250 patients supported by 2025.[2]
This model targets the underserved market of 1 in 7 couples affected by infertility, emphasizing equity through home delivery, donor sperm compatibility, and stress reduction by removing intercourse pressure.[3][4][6] Béa's momentum includes UK launch in 2023 after extensive R&D, £800K pre-launch funding in 2021, FDA Class 2 clearance in 2025, and US expansion.[2][3]
Béa Fertility was co-founded in 2021 in London by CEO Tess Isabelle Cosad, a femtech specialist frustrated by watching friends endure the emotional toll of delayed fertility support, and embryologist David O’Rourke, who brought clinical expertise.[1][2][3] Tess's personal motivation stemmed from observing the "try for 12 months and see" approach leave people isolated until crisis, prompting her to build a solution offering guidance from the first step.[1][2]
The idea emerged from recognizing ICI—a proven, simple insemination method—as overlooked for early use, despite its potential to boost conception odds by 40-60% over 3-6 months.[3][4] After two years of R&D with 90 prototypes and thousands of tests, Béa launched in the UK in 2023, secured £800K from Calm/Storm Ventures, QVentures, and InnovateUK, and hit pivotal milestones like high NPS scores and FDA clearance by 2025.[2][3]
Béa rides the femtech boom, addressing a $50B+ global fertility market strained by IVF inaccessibility (only 3% of needy patients access it) and rising infertility rates amid delayed parenthood.[2][3][6] Timing aligns with post-pandemic demand for telehealth and at-home diagnostics, amplified by FDA clearance enabling US entry amid clinician shortages and equity gaps.[1][2]
Market forces like aging demographics, donor sperm normalization, and taboo-breaking conversations favor Béa, which influences the ecosystem by proving ICI viability, aggregating fertility data for research, and shifting paradigms from "last-resort IVF" to proactive, inclusive care.[4][9] As a pioneer, it empowers patients, reduces system overload, and inspires hybrid clinic-home models.
Béa is poised for US dominance post-FDA clearance, scaling its 2,700-cycle base with data-driven iterations and partnerships like Pioneer Life Sciences Fund.[2][7] Trends like AI-enhanced assessments, expanded donor integration, and global femtech investment (building on its £800K raise) will propel growth, potentially capturing early-intervention market share as IVF costs soar.[3]
Its influence may evolve into a full fertility platform, deepening data insights to personalize care and advocate policy changes, ultimately redefining parenthood pathways from reactive to empowered—fulfilling Tess's vision of care "from day one, not month twelve."[2]
